Introduction
Cancer is one of the leading causes of death in the World. Cancer is usually very expensive and are also very difficult to treat. These treatments include chemotherapy, radiation, and hormone treatments. Many types of cancer require different treatments, and this makes it more difficult for doctors to figure out how to find a treatment plan that fits each patient specifically. There is an incredible need for a new anti-tumor therapy, especially with the increasing number of new cases of cancer.
The point of this project is to develop O-phenyl-N-(9’-acridine)-hydroxylamine and O-(4-bromo)-phenyl-N-(9’-acridine)-hydroxylamine. This will likely be an effective antitumor drug which is less susceptible to hydrolysis and will still act as a topoisomerase poison or catalytic inhibitor. A catalytic inhibitor stops the enzyme from working but leaves it there, while a poison just kills the enzyme and gets rid of it all together, although this drug will also affect healthy cells, cancer cells replicate more quickly so the drug will be effective for its purpose. The drug will cause apoptosis of cells by intercalating itself into DNA. This in turn will cause the cancer cells to stop growing and spreading and thus make it easier to treat it.
Already, some 9-aminoacridine derivatives have been produced and have been found to have antitumor characteristics however it is uncertain why it is this way. The current 2 options are either it is a topoisomerase poison or it is a catalytic inhibitor. In either case, if a version of the drug is synthesized, then there will be a novel antitumor drug. The end goal of this project is to figure out whether 9-aminoacridine and its derivatives are good antitumor drug and then to see if one is better than another. This will be assessed on how long the compound will stay bonded to the DNA, how many side effects it comes with, and how effective it is in getting rid of the cancer cells.
Already, some 9-aminoacridine derivatives have been produced and have been found to have antitumor characteristics however it is uncertain why it is this way. The current 2 options are either it is a topoisomerase poison or it is a catalytic inhibitor. In either case, if a version of the drug is synthesized, then there will be a novel antitumor drug. The end goal of this project is to figure out whether 9-aminoacridine and its derivatives are good antitumor drug and then to see if one is better than another. This will be assessed on how long the compound will stay bonded to the DNA, how many side effects it comes with, and how effective it is in getting rid of the cancer cells.